Company Dossier · Health Care
Veeva Systems
- S&P 500
- Russell 1000
What Veeva Systems is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to July 31, 2026: $3.46 billion, up 16% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to October 31, 2019: $0.42 billion, up 56% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to October 31, 2019: $0.01 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to January 31, 2026: $0.17 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 26, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed March 20, 2026): 1 risk factor added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $13.3 million on the open market.SEC Form 4
- 1,067 institutional managers reported a position at June 30, 2026 (+44 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 29 (42 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Veeva Systems is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding ↔ Retrenching
Withheld: 50% of the evidence is readable at this date (needs 60%).
- Capital spending—
- Debt raised—
- Buybacks vs capex—
- Hiring filings76th pct
- Deals and private raises49th pct
- Patent publications93rd pct
Confident ↔ Hedging
Confident
- Call sentiment82nd pct
- Call confidence63rd pct
- Guidance changes80th pct
- Risk factors added52nd pct
- Insider open-market trades44th pct
- + Call sentiment
- + Guidance changes
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver40th pct
- Stress filings48th pct
Credit
How these are built →No bond term sheets or tagged debt on file for Veeva Systems yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Veeva Systems, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralVeeva Systems Inc (VEEV) Stock Down 3.0% -- Now Undervalued? GF Score: 99/100
gurufocus.com · via Marketaux · Oct 2, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Sep 29, 2026Patent
- Sep 22, 2026Patent
- Sep 8, 2026Patent
- Aug 20, 20268-KDirector or officer changeItem 5.02
- Aug 14, 2026Trademark
- Jun 18, 20268-KShareholder vote resultsItem 5.07
- May 28, 2026Trademark
- May 28, 2026Trademark
- Apr 20, 20268-KDirector or officer changeItem 5.02
- Mar 20, 202610-KAnnual report (10-K)1 risk factors added, 1 removed
- Dec 11, 20258-KDirector or officer changeItem 5.02
- Dec 11, 2025Trademark
- Dec 11, 2025Trademark
- Nov 18, 20258-KDirector or officer changeItem 5.02
- Jun 23, 20258-KShareholder vote resultsItem 5.07
- Mar 24, 202510-KAnnual report (10-K)1 risk factors added, 1 removed
- Mar 12, 20258-KDirector or officer changeItem 5.02
- Mar 25, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Solventum SOLV | $8.3B | −$0.1B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| BioMarin Pharmaceutical BMRN | $3.4B | $0.7B | Jun 30, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| West Pharmaceutical Services WST | $3.3B | $0.4B | Jun 30, 2026 |
| Dentsply Sirona XRAY | $3.6B | $0.1B | Jun 30, 2026 |
| Alnylam Pharmaceuticals ALNY | $3.7B | $0.5B | Dec 31, 2025 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |